Search DIAN-TU Biospecimen Resource Requests
Aschenbrenner
Quantifying the impact of ARIA on cognition measured with computerized testing.
11/09/2023
Determine if ARIA produces measurable effects on cognition and quantify the effect size.
jing zhang
Research on the value of multi-layer network characteristics in the brain of patients with early-onset AD in disease diagnosis
01/06/2024
Exploring the changes in multi-layer network characteristics of the brain in patients with early-onset AD
Explore the value of multi-layer network features in disease diagnosis
NA
Alzheimer’s Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for ARIA Monitoring
02/06/2024
Review key MRI sequences for ARIA monitoring
Provide imaging recommendations for clinical practice
Highlight role of the radiologist in identifying and communicating ARIA findings
NA
Alzheimer’s Disease Clinical Trials: What have we learned from magnetic resonance imaging
02/06/2024
outline how MRI is used in eligibility and safety monitoring in AD clinical trials
review use of advanced MR imaging techniques in AD clinical trials
discuss opportunities for acceleration in MRI trial protocols
Klaus Romero
Model-informed drug development (MIDD) in Autosomal Dominant Alzheimer's Disease
05/31/2024
Our goal is to develop a comprehensive drug-disease-trial model across the entire disease continuum of Autosomal Dominant Alzheimer's Disease (ADAD). The drug-disease trial will serve as the foundation for a clinical trial simulation tool for ADAD
NA
Disappearing ARIA-H Microhemorrhages
06/27/2024
Demonstrate that ARIA-H microhemorrhages may resolve, rather than persist over time
Andrew Aschenbrenner
Establishing the utility and sensitivity of high-frequency cognitive assessments in Dominantly Inherited Alzheimer Disease.
06/28/2024
To quantify the cognitive effects of ADAD mutations, APOE genotype and AD biomarkers using a high-frequency cognitive assessment (HFCA) paradigm, the Ambulatory Research in Cognition (ARC) smartphone application.
Alexandre Bousse
Plug-and-play PET reconstruction
09/22/2024
Enhancing the quality of low-count PET images through a novel reconstruction method
Reducing patient dose and improving diagnostic
Proposing an AI-based reconstruction method with theoretical guarantees
Validation our method on two real patient data
Alexandre Bousse
Plug-and-play PET reconstruction
09/24/2024
Enhancing the quality of low-count PET images through a novel reconstruction method
Reducing patient dose and improving diagnostic
Proposing an AI-based reconstruction method with theoretical guarantees
Validation our method on two real patient data
Jorge J Llibre Guerra
Developing Predictive and Diagnostic Biomarkers for Amyloid-Related Imaging Abnormalities.
09/28/2024
Aim 1: Evaluate the Impact of ARIA on Clinical-Cognitive Performance and Treatment Outcomes.
Aim 2: Identify Clinical, Genetic, and Biomarker Predictors of ARIA Risk in Alzheimer's Disease.
Aim 3: Develop Biomarkers for ARIA occurrence and resolution in Alzheimer’s Disease.
Yi Su
Tracer harmonization for amyloid and tau PET imaging using statistical and deep learning techniques
09/28/2024
Explore harmonization of different tau tracers
Explore harmonization of different tau tracers
Explore impact of mixing tracers in clinical trials
null
To explore the causal relationship between gut microbiota and Alzheimer's disease (AD) by Mendelian randomization
10/29/2024
To explore the causal relationship between gut microbiota and Alzheimer's disease through Mendelian randomization, and write corresponding papers for journal publication
Dr. Hongxia Xu
On CSF biomarker screening in patients with Alzheimer's disease
11/19/2024
It is hoped that the complete CSF proteomics data will be used to screen for new, usable drug targets. It brings new perspectives for the treatment of AD patients.
None
Japan Webinar Deck 11th December
12/09/2024
We are using the images for a webinar to be held in Japan on 11 December. The images will be used for the presentation shown during the webinar.